A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard claims a British tanker it still holds, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
Ackman had teamed-up with Valeant to help the health care company try to buy the Botox maker. Their hostile pursuit, announced in April, was thwarted by Actavis, which agreed in November to buy Allergan in a $66 billion deal.
Pyott described the months following the Valeant offer and before the Actavis deal as "all-consuming."
The Allergan chief said on "Squawk Box " he had divided the management team—appointing President Doug Ingram and Chief Science Officer Scott Whitcup to run the day-to-day operations. "I will concentrate on the raiders, investors, public relations, all the above," he said.
"Between the day the Valeant offer was announced, April 22 and ... pretty much today, the value of the stock has increased about $20 billion. Part of that isn't a takeover premium at the end, but we constantly ramped up our performance," Pyott said.
Ackman's bet on Allergan netted about $2.2 billion—a big winner for his Pershing Square Capital Management whose main fund returned 40 percent last year, nearly four times the gain of the in 2014.